Learn About Hemolysis

INFORMATION

Red blood cells normally live for 110 to 120 days. After that, they naturally break down and are most often removed from the circulation by the spleen.

Some diseases and processes cause red blood cells to break down too soon. This requires the bone marrow to make more red blood cells than normal. The balance between red blood cell breakdown and production determines how low the red blood cell count becomes. If the red blood cell count becomes abnormally low, it is called hemolytic anemia.

Conditions that can cause hemolysis include:

  • Immune reactions
  • Infections
  • Medicines
  • Toxins and poisons
  • Red blood cell metabolism or defects in the shape of blood cells
What is the definition of Hemolysis?

Hemolysis is the breakdown of red blood cells.

Who are the top Hemolysis Local Doctors?
Robert A. Brodsky
Elite in Hemolysis
Pathology | Hematology | Oncology
Elite in Hemolysis
Pathology | Hematology | Oncology

Sidney Kimmel Comprehensive Cancer Center

401 North Broadway Street, Weinberg BLDG, Weinberg BLDG, 
Baltimore, MD 
Languages Spoken:
English

Dr. Robert Brodsky is a professor of medicine at the Johns Hopkins University School of Medicine. His area of clinical expertise is classical hematology and haploidentical bone marrow transplant for sickle cell disease and aplastic anemia. Dr. Brodsky serves as the director of the Division of Hematology and the T32 Training Program. He is the Johns Hopkins Family Professor of Medicine and Oncology. He received his M.D. from Hahnemann University. He completed his residency at the Vanderbilt University School of Medicine. He performed a fellowship in hematology at the National Institutes of Health and a fellowship in oncology at Johns Hopkins. He joined the Johns Hopkins faculty in 1997. From 2017 to 2022 he served as Associate Editor to The Journal of Clinical Investigation (JCI) and Secretary to American Society of Hematology (ASH). He serves as President of The American Society of Hematology (ASH) in 2023. Dr. Brodsky is rated as an Elite provider by MediFind in the treatment of Hemolysis. His top areas of expertise are Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Anemia, Bone Marrow Transplant, and Splenectomy.

Jaroslaw Maciejewski
Elite in Hemolysis
Elite in Hemolysis

Cleveland Clinic

8950 Euclid Ave, 
Cleveland, OH 
Languages Spoken:
English
Offers Telehealth

Jaroslaw Maciejewski is a Hematologist in Cleveland, Ohio. Dr. Maciejewski is rated as an Elite provider by MediFind in the treatment of Hemolysis. His top areas of expertise are Paroxysmal Nocturnal Hemoglobinuria (PNH), Aplastic Anemia, Paroxysmal Cold Hemoglobinuria, Bone Marrow Transplant, and Splenectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Jeffrey Szer
Elite in Hemolysis
Elite in Hemolysis
300 Grattan St, 
Parkville, VIC, AU 

Jeffrey Szer practices in Parkville, Australia. Szer is rated as an Elite expert by MediFind in the treatment of Hemolysis. Their top areas of expertise are Paroxysmal Cold Hemoglobinuria, Paroxysmal Nocturnal Hemoglobinuria (PNH), Hemolysis, Hemolytic Anemia, and Bone Marrow Transplant.

What are the latest Hemolysis Clinical Trials?
A Single-Center, Randomized, Crossover, Prospective, Open-Label, Non-Inferiority Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of an AI- and Ultrasound-Based Medical Device That Assists Venipuncture, Compared With Manual Venipuncture

Summary: Purpose : This study aims to confirm the safety and efficacy of AIIV L2, an artificial intelligence- and ultrasound-based medical device that assists venipuncture, by comparing venipuncture performed using AIIV L2 with manual venipuncture. Study Design : This is a single-center, randomized, crossover, prospective, open-label, non-inferiority confirmatory clinical trial. Methods : Each participant ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Single Arm Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Control of Intravascular Hemolysis on Currently Available C5 Inhibitor Therapy

Summary: This study is researching a treatment combination with two experimental drugs called pozelimab and cemdisiran referred to as study drugs. Researchers are looking for a better way to treat Paroxysmal Nocturnal Hemoglobinuria (PNH). The aim of the study is to see how well the pozelimab and cemdisiran combination works to lower hemolysis in participants whose PNH has been not well controlled even aft...

Who are the sources who wrote this article ?

Published Date: March 31, 2024
Published By: Todd Gersten, MD, Hematology/Oncology, Florida Cancer Specialists & Research Institute, Wellington, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

What are the references for this article ?

Elghetany MT, Banki K. Erythrocytic disorders. In: McPherson RA, Pincus MR, eds. Henry's Clinical Diagnosis and Management by Laboratory Methods. 24th ed. Philadelphia, PA: Elsevier; 2022:chap 33.

Gallagher PG. Red blood cell membrane disorders. In: Hoffman R, Benz EJ, Silberstein LE, et al, eds. Hematology: Basic Principles and Practice. 8th ed. Philadelphia, PA: Elsevier; 2023:chap 46.

Gallagher PG. Hemolytic anemias: red blood cell membrane and metabolic defects. In: Goldman L, Cooney KA, eds. Goldman-Cecil Medicine. 27th ed. Philadelphia, PA: Elsevier; 2024:chap 147.

Gregg XT, Prchal JT. Red blood cell enzymopathies. In: Hoffman R, Benz EJ, Silberstein LE, et al, eds. Hematology: Basic Principles and Practice. 8th ed. Philadelphia, PA: Elsevier; 2023:chap 45.

Mentzer WC, Schrier SL. Extrinsic nonimmune hemolytic anemias. In: Hoffman R, Benz EJ, Silberstein LE, et al, eds. Hematology: Basic Principles and Practice. 8th ed. Philadelphia, PA: Elsevier; 2023:chap 48.

Michel M. Autoimmune and intravascular hemolytic anemias. In: Goldman L, Cooney KA, eds. Goldman-Cecil Medicine. 27th ed. Philadelphia, PA: Elsevier; 2024:chap 146.